Biomet reported a net sales increase of 3 percent worldwide to approximately $740 million, while sales in the U.S. alone increased 7 percent for the fourth quarter. The device manufacturer saw growth in knee sales (4 percent worldwide), hip sales (3 percent worldwide), sports medicine sales (19 percent worldwide) and extremity sales (20 percent worldwide).
"I'm extremely pleased with our fiscal fourth quarter sales results, which were strong across numerous product categories. In a separate release today, we announced the initial closing of the DePuy trauma acquisition and we're very excited about the additional opportunities we believe this business will bring to Biomet," said Biomet President and CEO Jeffrey R. Binder. "As we exit fiscal year 2012 with a strong finish to our consolidated sales results and welcome the addition of our new trauma team members, we look forward with much enthusiasm to the possibilities in fiscal year 2013."
"I'm extremely pleased with our fiscal fourth quarter sales results, which were strong across numerous product categories. In a separate release today, we announced the initial closing of the DePuy trauma acquisition and we're very excited about the additional opportunities we believe this business will bring to Biomet," said Biomet President and CEO Jeffrey R. Binder. "As we exit fiscal year 2012 with a strong finish to our consolidated sales results and welcome the addition of our new trauma team members, we look forward with much enthusiasm to the possibilities in fiscal year 2013."
Related Articles on Biomet:
43 Orthopedic & Spine Devices Receive FDA Clearance in May
Biomet Closes DePuy Trauma Acquisition
Biomet Makes $280M Offer on DePuy's Trauma Business